Hydrocortisone with or without mitoxantrone in men with hormone- refractory prostate cancer: Results of the cancer and leukemia group B 9182 study

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2506-2513

  Kantoff, Philip W ^a   Halabi, Susan ^a   Conaway, Mark ^a   Picus, Joel ^a   Kirshner, Jeffrey ^a   Hars, Vera ^a   Trump, Donald ^a   Winer, Eric P ^a   Vogelzang, Nicholas J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; DOXORUBICIN; HYDROCORTISONE; MITOXANTRONE;

AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032784113     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2506     Document Type: Article

References (25)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 1:6-29, 1998
2. Eisenberger MA, Simon R, O'Dwyer PJ, et al: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 6:827-841, 1985
3. Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and QOL as pragmatic indices of response. J Clin Oncol 5:590-597, 1989
4. Kantoff PW, Block C, Letvak L, et al: 14-Day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate. Am J Clin Oncol 6:489-491, 1993
5. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 6:1756-1764, 1996
6. Lan KKG, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
7. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
8. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized blincial trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
9. Cox DR: Regression models and life tables (with discussion). J Royal Stat Soc B 74:187-220, 1974
10. Laird NM, Ware JH: Random-effects models for longitudinal data. Biometrics 38:963-974, 1982
11. Schipper CJ, McMurray A, Levitt M: Measuring the quality of life of cancer patients: The functional living index-cancer: Development and validation. J Clin Oncol 2:472-483, 1984
12. McCorkle R, Young K: Development of a symptom distress scale. Cancer Nurs 1:373-378, 1978
13. Fossa S, Aaronson N, Newling D: Quality of life and treatment of hormone-resistant metastatic prostate cancer. Eur J Cancer 26:1133-1136, 1990
14. Brook RH, Ware JE Jr, Davies-Avery A: Conceptualization and Measurement of Health for Adults in the Health Insurance Study, vol VIII, Overview. Santa Monica, CA, Rand, 1979
15. Dant RL, Cleeland CS, Flanery RC: Development of the Wisconsin brief pain questionnaire to assess pain in cancer and other diseases. Pain 17:197-210, 1983
16. Berry WR, Laszlo J, Cox E, et al: Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44:763-775, 1979
17. Dewys WD, Begg CB, Brodovsky H, et al: Comparative clinical trial of Adriamycin and 5-florouracil in advanced prostatic cancer: Prognostic factors and response. Prostate 4:1-11, 1983
18. Emrich LJ, Priore RL, Murphy GP, et al: Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45:5173-5179, 1985
19. Manni A, Bartholomew M, Caplan R, et al: Androgen priming and chemotherapy in advanced prostate cancer evaluation of determinants of clinical outcome. J Clin Oncol 6:1456-1466, 1988
20. Fossa SD, Paus E, Lindegaard M, et al: Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostate cancer undergoing experimental treatment. Br J Urol 69:175-179, 1992
21. Petrylak DP, Scher HI, Li Z, et al: Prognostic factors for survival of patients with bidemensionally measurable metastatic hormone-refractory prostate cancer treated with single-agent chemotherapy. Cancer 70:2870-2878, 1992
22. Kelly WK, Scher HI, Mazumdar M, et al: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11:607-615, 1993
23. Sridhara R, Eisenberger MA, Sinibaldi VJ, et al: Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13:2944-2953, 1995
24. Pienta KJ, Redman BG, Bandekar R, et al: A phase II trial of oral estramustine and oral etoposide in hormone-refractory prostate cancer. Urology 50:401-407, 1997
25. Smith DC, Dunn RL, Strawderman MS, et al: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16:1835-1843, 1998